Companies › Avacta Life Sciences
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AVA6000 FAP-activated doxorubicin prodrug | FAP | Phase 1 | Salivary Gland Tumor | Aug 2027 |
| AVA6103 FAP-activated Exatecan | FAP | Phase 1 | Vulvar Adenocarcinoma | Jan 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04969835 | AVA6000 | Phase 1 | Salivary Gland Tumor | Oncology | Aug 2027 |
| NCT07454642 | AVA6103 | Phase 1 | Vulvar Adenocarcinoma | Oncology | Jan 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.